FDA Approval Status of Dietary Supplements for Anxiety
No dietary supplements are FDA-approved for the treatment of anxiety. The FDA does not approve dietary supplements as therapeutic agents for any medical condition, including anxiety disorders 1, 2, 3, 4.
Regulatory Framework
Dietary supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA), not as drugs, which means they do not undergo the rigorous premarket approval process required for pharmaceutical treatments 2, 3.
The FDA only regulates supplements for safety concerns post-market, not for efficacy in treating medical conditions like anxiety 3, 4.
Supplements cannot legally claim to treat, cure, or prevent diseases without FDA approval as drugs, which none currently have for anxiety 3.
Evidence-Based First-Line Treatments for Anxiety
Since no supplements have FDA approval, first-line pharmacotherapy for anxiety disorders consists of SSRIs (such as sertraline) and SNRIs (such as venlafaxine extended-release), which demonstrate small to medium effect sizes compared to placebo 5, 6.
- Cognitive behavioral therapy represents the psychotherapy with the highest level of evidence for anxiety disorders, showing large effect sizes (Hedges g = 1.01 for generalized anxiety disorder) 5, 6.
Natural Products with Safety Data (Not FDA-Approved)
While not FDA-approved, certain natural products have been studied for anxiety management:
Products with Better Safety Profiles in Polytherapy
Lavender demonstrates an excellent safety profile with no sedative effects, no drug abuse potential, and can be safely continued perioperatively without anesthetic interactions 7, 8.
The Society for Integrative Oncology-ASCO guidelines recommend lavender essential oil inhalation for anxiety during cancer-related procedures, though this is not FDA approval for anxiety treatment 8.
Melatonin, passiflora, and lavender are recommended by the American College of Cardiology as having well-documented safety profiles with minimal pharmacological interactions in polytherapy patients 7.
Products Requiring Caution or Avoidance
Kava should be avoided due to risk of excessive sedation when combined with anesthetics, benzodiazepines, and opioids 7.
St. John's Wort induces cytochrome P450 3A4, reducing plasma concentrations of numerous medications and should be suspended 2 weeks before procedures 7.
L-tryptophan carries risk of serotonin syndrome when combined with serotonin reuptake inhibitors 7.
Critical Clinical Considerations
Herbal supplements are not regulated by the FDA to provide evidence of therapeutic claims, contribute to medication burden, have drug interaction concerns, and show poor to no evidence of pharmacological benefit 1.
Impurities, adulterants, and highly variable active ingredient content have been documented in supplement products due to lack of good manufacturing practice requirements 3.
More than 80% of severe adverse reactions from natural products are type A (dose-dependent and predictable) and therefore avoidable with proper monitoring 7.
All natural products should be documented in the medical record as part of medication reconciliation, with particular attention to patients on anticoagulants, antiplatelets, antidiabetics, or cardiovascular medications 7.